12:10 PM EDT, 07/23/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday that phase 2b/3 clinical trial evaluating clesrovimab in infant patients with respiratory syncytial virus disease, or RSV, met its primary safety and efficacy endpoints.

The primary goal included reduced medically attended lower respiratory infections from RSV on day 150. The company will present detailed findings from the trial at an upcoming scientific congress.

Price: 125.13, Change: -0.56, Percent Change: -0.45